Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1422-1427

  Psyrri, A ^a   Kalogeras, K T ^b,c   Kronenwett, R ^d,k   Wirtz, R M ^d,l   Batistatou, A ^e   Bournakis, E ^f   Timotheadou, E ^b   Gogas, H ^g   Aravantinos, G ^h   Christodoulou, C ⁱ   Makatsoris, T ^j   Linardou, H ⁱ   Pectasides, D ^g   Pavlidis, N ^e   Economopoulos, T ^a   Fountzilas, G ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d SIEMENS AG   (Germany)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f ALEXANDRA HOSPITAL   (United Kingdom)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h AGII ANARGIRI CANCER HOSPITAL   (Greece)

ⁱ METROPOLITAN HOSPITAL   (Greece)

^j UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^k Sividon Diagnostics GmbH   (Germany)

^l STRATIFYER Molecular Pathology GmbH   (Germany)

more..

Author keywords

Breast cancer; Mrna; Predictive value; Prognostic value; Qrt PCR; UBE2C

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PROTEIN UBE2C; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE SEQUENCE; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; TISSUE SECTION;

EID: 84861722853     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr527     Document Type: Article

References (33)

1. Harper JW, Burton JL, Solomon MJ. The anaphase-promoting complex: it's not just for mitosis any more. Genes Dev 2002; 16(17): 2179-2206.
2. Peters B, Janek K, Kuckelkorn U, Holzhutter HG. Assessment of proteasomal cleavage probabilities from kinetic analysis of time-dependent product formation. J Mol Biol 2002; 318(3): 847-862.
3. Mayer RJ. The meteoric rise of regulated intracellular proteolysis. Nat Rev Mol Cell Biol 2000; 1(2): 145-148.
4. Townsley FM, Aristarkhov A, Beck S et al. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A 1997; 94(6): 2362-2367.
5. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001; 98(3): 1176-1181.
6. LaTulippe E, Satagopan J, Smith A et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62(15): 4499-4506.
7. Okamoto Y, Ozaki T, Miyazaki K et al. UbcH10 is the cancer-related E2 ubiquitinconjugating enzyme. Cancer Res 2003; 63(14): 4167-4173.
8. Wagner KW, Sapinoso LM, El-Rifai W et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 2004; 23(39): 6621-6629.
9. Barbareschi M, Girlando S, Mauri FM et al. Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 1994; 102: 171-175.
10. Kennedy JC, El-Badawy N, DeRose PB, Cohen C. Comparison of cell proliferation in breast carcinoma using image analysis (Ki-67) and flow cytometric systems. Anal Quant Cytol Histol 1992; 14: 304-311.
11. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
12. Oakman C, Bessi S, Zafarana E et al. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009; 11: 205.
13. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; 20: 1319-1329.
14. Fountzilas G, Skarlos D, Dafni U et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16(11): 1762-1771.
15. Galea MH, Blamey RW, Elston CH et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-219.
16. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28(16): 2784-2795.
17. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
18. Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
19. Pentheroudakis G, Batistatou A, Kalogeras KT et al. Prognostic utility of b-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 2011; 127(1): 179-193.
20. Bohmann K, Hennig G, Rogel U et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 2009; 55: 1719-1727.
21. Mueller BM, Kronenwett R, Hennig G et al. Quantitative determination of estrogen receptor, progesterone receptor and HER2 mRNA in formalin-fixed paraffinembedded tissue-a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 2011; 20: 1-10.
22. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25(15): 2127-2132.
23. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100(2): 229-235.
24. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101(21): 1446-1452.
25. Jezequel P, Campone M, Roche H et al. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat 2009; 116: 509-520.
26. Berlingieri MT, Pallante P, Sboner A et al. UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer 2007; 43(18): 2729-2735.
27. Loussouarn D, Campion L, Leclair F et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer 2009; 101(1): 166-173.
28. Chen L, Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes and eEF1A translation factor detected in breast cancer tissue. Cancer Res 2005; 65(13): 5599-5606.
29. Deng S, Zhou H, Xiong R et al. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat 2007; 104(1): 21-30.
30. Ciechanover A. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 2003; 31(2): 474-481.
31. Orlowski RZ, Voorhees PM, Garcia RA et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105(8): 3058-3065.
32. Sato K, Rajendra E, Ohta T. The UPS: a promising target for breast cancer treatment. BMC Biochem 2008; 9(1): S2.
33. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003; 29(1): 21-31.